ESR1 and breast cancer: In the Nurses’ Health Study II, current OC use for more than 5 years was associated with an increased risk of ER-positive/PR-positive/ERBB2-negative breast cancer,9 comparable to the associations we found for luminal A–like and luminal B–like tumors.